Listed

Chemed Corp: Form 10-Q for the period ended Sep 30, 2026

Filed with the SEC on Oct 29, 2026 and accepted by EDGAR at Oct 29, 2026, 09:00 ET.

Share

Management's discussion and analysis

As filed, 50,450 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, excavation, water restoration, and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world. We continue to monitor macroeconomic trends and uncertainties such as inflation, the effects of recently implemented tariffs, and the potential imposition of modified or additional tariffs, as well as the impact of the war with Iran on fuel prices, which may have adverse effects on net sales and profitability. Based on preliminary analysis of the potential effects of the announced tariffs and these other factors, while we have realized an increase in fuel costs, which has affected our margins, we do not expect a material negative effect on our net sales or profitability for the remainder of fiscal year 2026. However, we are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts for fiscal year 2027 planning. Economic pressures including the challenges of high inflation and the effects of increased tariffs and the impact of the war with Iran may negatively affect our net sales and profitability in the future.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended September 30, 2026 2025 Nine months ended September 30, 2026 2025
Service revenues and sales $690,940 $624,900 $2,021,704 $1,890,641
Net income $71,648 $64,237 $205,653 $188,487
Diluted EPS $5.45 $4.46 $15.43 $12.89
Adjusted net income $88,725 $75,906 $246,146 $221,701
Adjusted diluted EPS $6.75 $5.27 $18.47 $15.16
Adjusted EBITDA $133,785 $109,045 $371,847 $326,070
Adjusted EBITDA as a % of revenue 19.4% 17.4% 18.4% 17.2%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 39-41.

For the three months ended September 30, 2026, the increase in consolidated service revenues and sales was driven by a 12.2% increase at VITAS and a 7.5% increase at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.2%. Acuity mix shift negatively impacted revenue growth by 25-basis points in the quarter when compared to the prior year quarter’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes increased revenue growth by 85-basis points. The increase in service revenues at Roto-Rooter was driven by an increase in all service lines.

For the nine months ended September 30, 2026, the increase in consolidated service revenues and sales was driven by a 9.0% increase at VITAS and by a 3.2% increase at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of 5.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.4%. Acuity mix shift negatively impacted revenue growth by 89-basis points in the year when compared to the prior year’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes increased revenue growth by 159-basis points. The increase in service revenues at Roto-Rooter was driven by an increase in plumbing, drain cleaning and excavation offset by a decrease in water restoration and in the Independent Contractors.

On September 16, 2026, Roto-Rooter completed the acquisition of RotoCo, LLC (“RotoCo”), the largest independent Roto-Rooter franchise for $60.6 million using borrowings under Chemed’s existing $450.0 million revolving credit facility. The territories acquired include Northern San Diego, Palm Springs, Ventura, Bakersfield, Lancaster, Fresno, Monterey, Stockton, Manteca and Sacramento, California.

Other acquisitions completed in 2026 include the following, in the third quarter of 2026, Roto-Rooter completed one acquisition for one franchise in California for a total of $1.9 million in cash. In the second quarter of 2026, Roto-Rooter completed two acquisitions for one franchise in New York and one franchise in Texas for a total of $12.9 million in cash. In the first quarter of 2026, Roto-Rooter completed two acquisitions for one franchise in Texas and one franchise in California for a total of $20.6 million in cash.

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2025 to September 30, 2026 include the following:

A $72.3 million increase in accounts receivable due primarily to the timing of payments received from the Federal government at VITAS. We typically receive a payment in excess of $63.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

An $11.5 million increase in prepaid expenses due primarily to renewal of insurance policies during the year.

A $12.9 million increase in lease right of use asset due to lease renewals. This resulted in a similar increase in the lease liability accounts.

An $87.8 million increase in goodwill due to the six acquisitions at Roto-Rooter.

A $15.0 million increase in accrued insurance related to a $6.0 million legal settlement of a casualty insurance claim and an increase in casualty and medical insurance expenses.

A $30.7 million increase in accrued compensation due to yearly bonus accruals and timing of payroll at VITAS.

A $236.0 million increase in long-term debt due primarily to acquisitions and stock repurchases.

A $400.0 million increase in treasury stock due to stock repurchases.

Net cash provided by operating activities decreased $25.1 million from September 30, 2025 to September 30, 2026. See the Unaudited Consolidated Statements of Cash Flows on page 5 for the detail components making up the change.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

Commitments and Contingencies

On April 10, 2026, we replaced the Prior Credit Agreement with a sixth amended and restated Credit Agreement. Terms of the Credit Agreement consist of a five-year $450.0 million revolving credit facility including $100.0 million for letters of credit. This Credit Agreement has a floating interest rate that is generally the secured overnight financing rate (“SOFR”) plus an additional tiered rate which varies based on our current leverage ratio. As of September 30, 2026, the interest rate is SOFR plus 100 basis points. The Credit Agreement includes an expansion feature that provides the Company the opportunity to increase its revolver by an additional $250.0 million.

We have issued $47.3 million in standby letters of credit as of September 30, 2026, mainly for insurance purposes. Issued letters of credit reduce our available credit under the Credit Agreement. As of September 30, 2026, we have approximately $166.7 million of unused lines of credit available and are eligible to be drawn down under the Credit Agreement. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Collectively, the terms of the Credit Agreement require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of September 30, 2026.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 11 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

Results of Operations

Three months ended September 30, 2026 versus 2025 - Consolidated Results

Our service revenues and sales for the third quarter of 2026 increased 10.6% versus services revenue and sales for the third quarter of 2025. Of this increase, a $49.7 million increase was attributable to VITAS, and a $16.4 million increase was attributable to Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Three months ended September 30, 2026 2025 Increase/(Decrease) Percent
Routine homecare $405,969 $362,405 12.0
General inpatient 36,407 33,099 10.0
Continuous care 21,159 19,946 6.1
Other 6,421 5,807 10.6
Subtotal 469,956 421,257 11.6
Medicare cap adjustment (828) (6,086) 86.4
Room and board - net (3,982) (3,859) (3.2)
Implicit price concessions (7,743) (3,571) (116.8)
Net revenue $457,403 $407,741 12.2
Roto-Rooter
Drain cleaning $58,475 $55,454 5.4
Plumbing 48,242 45,753 5.4
Excavation 61,249 57,102 7.3
Other 355 220 61.4
Subtotal - short term core 168,321 158,529 6.2
Water restoration 48,882 45,196 8.2
Independent contractors 16,867 16,871 (0.0)
Outside franchisee fees 1,575 1,433 9.9
Other 4,262 4,449 (4.2)
Gross revenue 239,907 226,478 5.9
Implicit price concessions (6,370) (9,319) 31.6
Net revenue 233,537 217,159 7.5
Total Revenues $690,940 $624,900 10.6

Days of care at VITAS during the quarters were as follows:

Three months ended September 30, 2026 2025 Increase/(Decrease) Percent
Routine homecare 1,872,071 1,685,859 11.0
Nursing home 312,663 309,192 1.1
Respite 12,502 12,184 2.6
Subtotal routine homecare and respite 2,197,236 2,007,235 9.5
General inpatient 30,494 28,530 6.9
Continuous care 19,683 18,309 7.5
Total days of care 2,247,413 2,054,074 9.4

The increase in service revenues at VITAS is comprised primarily of 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.2%. Acuity mix shift negatively impacted revenue growth by 25-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes increased revenue growth by 85-basis points.

The increase in plumbing revenues for the third quarter of 2026 versus 2025 is attributable to a 10.5% increase in price and service mix shift offset by a 5.1% decrease in job count. The increase in drain cleaning revenues for the third quarter of 2026 versus 2025 is attributable to a 6.4% increase in price and service mix offset by a 1.0% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, excavation revenues increased 7.3% and water restoration revenues increased 8.2%. Implicit price concessions and credit memos decreased 31.6% mainly related to the improved collections in water restoration business.

The consolidated gross margin was 33.7% in the third quarter of 2026 as compared with 32.0% in the third quarter of 2025. On a segment basis, VITAS’ gross margin was 25.2% in the third quarter of 2026 as compared with 22.0% in the third quarter of 2025. The increase was primarily related to increased revenues including a $5.3 million decrease in Medicare Cap billing limitation in the third quarter of 2026 compared to third quarter of 2025 as well as continued focus on expense control. The Roto-Rooter segment’s gross margin was 50.3% for the third quarter of 2026 which was almost equal to the third quarter of 2025.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended September 30, 2026 2025
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $106,241 $99,288
Impact of market value adjustments related to assets held in deferred compensation trusts 2,077 6,703
Long-term incentive compensation 3,151 (216)
Total SG&A expenses $111,469 $105,775

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the third quarter of 2026 were up 7.0% when compared to the third quarter of 2025. Of this increase $4.3 million was the result of increased advertising at Roto-Rooter in the third quarter of 2026 compared to the third quarter of 2025. The remaining increase was the result of normal salary increases and increased incentive compensation.

Other operating expense (in thousands):

Three months ended September 30, 2026 2025
Legal settlements $7,483 $2,850
Loss on disposal of fixed assets 187 148
Total other operating expenses $7,670 $2,998

Other income – net comprise (in thousands):

Three months ended September 30, 2026 2025
Market value adjustment on assets held in deferred compensation trusts $2,077 $6,703
Interest income 295 2,555
Other 11 (7)
Total other income - net $2,383 $9,251

We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. Chemed invests excess cash in money market funds holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

Three months ended September 30, 2026 2025
Income tax provision calculated at the statutory federal rate $20,308 $17,544
State and local income taxes, less federal income tax effect 2,685 3,120
Nondeductible expenses:
Stock compensation tax expense 521 -
Other--net 1,546 (1,357)
Income tax provision $25,060 $19,307
Effective tax rate 25.9% 23.1%
  • 30-

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

VITAS Three months ended September 30, 2026 2025
Legal settlements $(5,076) $(2,152)
Roto-Rooter
Amortization of reacquired franchise agreements (1,804) (1,806)
Acquisition expense (1,324) -
Corporate
Stock option expense (5,284) (5,259)
Long-term incentive compensation (2,830) 213
Excess tax expenses on stock compensation (521) -
Legal settlements (238) -
Other - (2,665)
Total $(17,077) $(11,669)

Three months ended September 30, 2026 versus 2025 - Segment Results

Net income/(loss) for the third quarter of 2026 versus the third quarter of 2025 by segment (in thousands):

Three months ended September 30, 2026 2025
VITAS $65,708 $46,771
Roto-Rooter 30,140 32,071
Corporate (24,200) (14,605)
$71,648 $64,237

After-tax earnings as a percent of revenue at VITAS in the third quarter of 2026 was 14.4% as compared to 11.5% in the third quarter of 2025. VITAS’ after-tax earnings increased primarily due to increased revenues including a $5.3 million decrease in Medicare Cap liability in the third quarter of 2026 compared to the third quarter of 2025.

Roto-Rooter’s net income was negatively impacted in the third quarter of 2026 compared to the third quarter of 2025 due to an increase in marketing, fuel, and acquisition expenses. Roto-Rooter’s after-tax earnings as a percent of revenue in the third quarter of 2026 was 13.0%, as compared to 14.8% in the third quarter of 2025.

After-tax Corporate expenses for the third quarter of 2026 increased 65.7% when compared to the third quarter in 2025 due primarily to a $2.3 million decrease in interest income related to lower cash and investment balances, a $1.6 million increase in interest expense related to an increase in long-term debt as a result of stock repurchases and acquisitions, a $1.6 million increase in intercompany interest expense, a $3.1 million increase in stock-based compensation and a $520,000 decrease in excess tax benefit related to reduced stock option exercises.

Results of Operations

Nine months ended September 30, 2026 versus 2025 - Consolidated Results

Our service revenues and sales for the first nine months of 2026 increased 6.9% versus services revenue and sales for the first nine months of 2025. Of this increase, a $109.4 million increase was attributable to VITAS, and a $21.6 million increase was attributable to Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Nine months ended September 30, 2026 2025 Increase/(Decrease) Percent
Routine homecare $1,168,407 $1,072,014 9.0
General inpatient 108,006 100,145 7.8
Continuous care 58,689 68,222 (14.0)
Other 18,204 16,898 7.7
Subtotal 1,353,306 1,257,279 7.6
Medicare cap adjustment (3,703) (24,786) 85.1
Room and board - net (11,178) (11,277) 0.9
Implicit price concessions (17,663) (9,875) (78.9)
Net revenue $1,320,762 $1,211,341 9.0
Roto-Rooter
Drain cleaning $175,710 $170,553 3.0
Plumbing 145,727 137,097 6.3
Excavation 186,322 177,833 4.8
Other 856 595 43.9
Subtotal - short term core 508,615 486,078 4.6
Water restoration 143,587 149,183 (3.8)
Independent contractors 51,751 52,682 (1.8)
Outside franchisee fees 4,539 4,262 6.5
Other 13,649 14,127 (3.4)
Gross revenue 722,141 706,332 2.2
Implicit price concessions (21,199) (27,032) 21.6
Net revenue 700,942 679,300 3.2
Total Revenues $2,021,704 $1,890,641 6.9

Days of care at VITAS during the nine months ended September 30 were as follows:

Nine months ended September 30, 2026 2025 Increase/(Decrease) Percent
Routine homecare 5,356,050 4,980,883 7.5
Nursing home 910,534 923,458 (1.4)
Respite 35,684 33,619 6.1
Subtotal routine homecare and respite 6,302,268 5,937,960 6.1
General inpatient 90,671 86,447 4.9
Continuous care 55,065 62,576 (12.0)
Total days of care 6,448,004 6,086,983 5.9

The increase in service revenues at VITAS is comprised primarily of 5.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.4%. Acuity mix shift negatively impacted revenue growth by 89-basis points in the year when compared to the prior year revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes increased revenue growth by 159-basis points.

The increase in plumbing revenues for the first nine months of 2026 versus 2025 is attributable to an 11.6% increase in price and service mix shift offset by a 5.3% decrease in job count. The increase in drain cleaning revenues for the first nine months of 2026 versus 2025 is attributable to an 8.5% increase in price and service mix offset by a 5.5% decrease in job count. The increase in excavation revenues for the first nine months of 2026 versus 2025 is attributable to a 6.6% increase in price and service mix shift offset by a 1.8% decrease in job count. Water restoration revenues decreased 3.8%, and contractors operations decreased 1.8%. Implicit price concessions and credit memos decreased 21.6% mainly related to the improved collections in water restoration business.

The consolidated gross margin was 33.2% in the first nine months of 2026 as compared with 31.8% in the first nine months of 2025. On a segment basis, VITAS’ gross margin was 23.9% in the first nine months of 2026 as compared with 21.5% in the first nine months of 2025. The increase was primarily related to increased revenues including a $21.1 million decrease in Medicare Cap billing limitation in the first nine months of 2026 compared to the first nine months of 2025 as well as continued focus on expense control. The Roto-Rooter segment’s gross margin was 50.6% for the first nine months of 2026 which was almost equal to the first nine months of 2025.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Nine months ended September 30, 2026 2025
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $324,428 $301,600
Impact of market value adjustments related to assets held in deferred compensation trusts 9,661 6,791
Long-term incentive compensation 6,904 3,294
Total SG&A expenses $340,993 $311,685

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first nine months of 2026 were up 7.6% when compared to the first nine months of 2025. $11.1 million of this increase was the result of increased advertising at Roto-Rooter in the first nine months of 2026 compared to the first nine months of 2025. The remaining increase was the result of normal salary increases and increased incentive compensation.

Other operating expense (in thousands):

Nine months ended September 30, 2026 2025
Legal settlements $7,483 $2,850
Loss on disposal of fixed assets 257 225
Total other operating (income)/expenses $7,740 $3,075

Other income – net comprise (in thousands):

Nine months ended September 30, 2026 2025
Market value adjustment on assets held in deferred compensation trusts $9,661 $6,791
Interest income 1,399 7,186
Other 11 (7)
Total other income - net $11,071 $13,970

We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. Chemed invests excess cash in money market funds holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

Nine months ended September 30, 2026 2025
Income tax provision calculated at the statutory federal rate $58,144 $52,570
State and local income taxes, less federal income tax effect 8,213 9,568
Nondeductible expenses:
Stock compensation tax expense/(benefit) 1,022 (513)
Other--net 3,845 221
Income tax provision $71,224 $61,846
Effective tax rate 25.7% 24.7%
  • 33-

Net income for both periods include the following after tax items/adjustments that (reduce) or increased after tax earnings (in thousands):

VITAS Nine months ended September 30, 2026 2025
Legal settlements $(5,491) $(2,152)
Acquisition expense (6) -
Roto-Rooter
Amortization of reacquired franchise agreements (5,412) (5,419)
Acquisition expense (1,497) -
Corporate
Stock option expense (20,638) (20,576)
Long-term incentive compensation (6,189) (2,915)
Excess tax (expenses)/benefits on stock compensation (1,022) 513
Legal settlements (238) -
Other - (2,665)
Total $(40,493) $(33,214)

Nine months ended September 30, 2026 versus 2025 - Segment Results

Net income/(loss) for the first nine months of 2026 versus the first nine months of 2025 by segment (in thousands):

Nine months ended September 30, 2026 2025
VITAS $178,827 $135,021
Roto-Rooter 97,837 103,928
Corporate (71,011) (50,462)
$205,653 $188,487

After-tax earnings as a percent of revenue at VITAS in the first nine months of 2026 was 13.5% as compared to 11.1% in the first nine months of 2025. The increase was primarily related to increased revenues including a $21.1 million decrease in Medicare Cap liability in the first nine months of 2026 compared to the first nine months of 2025.

Roto-Rooter’s net income was negatively impacted in the first nine months of 2026 compared to the first nine months of 2025 due mainly to an increase in marketing, fuel, and acquisition expenses. Roto-Rooter’s after-tax earnings as a percent of revenue in the first nine months of 2026 was 14.0%, as compared to 15.3% in the first nine months of 2025.

After-tax Corporate expenses for the first nine months of 2026 increased 40.7% when compared to the first nine months in 2025 due primarily to a $5.8 million decrease in interest income related to lower cash and investment balances, a $3.2 million increase in interest expense related to an increase in long-term debt as a result of stock repurchases and acquisitions, a $4.8 million increase in intercompany interest expense, a $3.3 million increase in stock-based compensation and a $1.5 million decrease in excess tax benefit related to reduced stock option exercises.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026

(in thousands)(unaudited)

2026 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $457,403 $233,537 $- $690,940
Cost of services provided and goods sold 341,993 115,985 - 457,978
Selling, general and administrative expenses 23,100 71,033 17,336 111,469
Depreciation 5,791 8,624 12 14,427
Amortization 25 2,949 - 2,974
Other operating expense 7,352 88 230 7,670
Total costs and expenses 378,261 198,679 17,578 594,518
Income/(loss) from operations 79,142 34,858 (17,578) 96,422
Interest expense (54) (145) (1,898) (2,097)
Intercompany interest income/(expense) 6,766 4,574 (11,340) -
Other income—net 124 5 2,254 2,383
Income/(expense) before income taxes 85,978 39,292 (28,562) 96,708
Income taxes (20,270) (9,152) 4,362 (25,060)
Net income/(loss) $65,708 $30,140 $(24,200) $71,648
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Legal settlements $(6,705) $- $(308) $(7,013)
Stock option expense - - (5,984) (5,984)
Long-term incentive compensation - - (3,151) (3,151)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Acquisition expense - (1,726) - (1,726)
Total $(6,705) $(4,078) $(9,443) $(20,226)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Legal settlements $(5,076) $- $(238) $(5,314)
Stock option expense - - (5,284) (5,284)
Long-term incentive compensation - - (2,830) (2,830)
Amortization of reacquired franchise agreements - (1,804) - (1,804)
Acquisition expense - (1,324) - (1,324)
Excess tax expense on stock compensation - - (521) (521)
Total $(5,076) $(3,128) $(8,873) $(17,077)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025

(in thousands)(unaudited)

2025 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $407,741 $217,159 $- $624,900
Cost of services provided and goods sold 318,015 107,128 - 425,143
Selling, general and administrative expenses 25,236 60,672 19,867 105,775
Depreciation 5,354 8,298 12 13,664
Amortization 26 2,544 - 2,570
Other operating expense/(income) 3,036 (38) - 2,998
Total costs and expenses 351,667 178,604 19,879 550,150
Income/(loss) from operations 56,074 38,555 (19,879) 74,750
Interest expense (56) (132) (269) (457)
Intercompany interest income/(expense) 5,685 4,030 (9,715) -
Other income—net 61 25 9,165 9,251
Income/(expense) before income taxes 61,764 42,478 (20,698) 83,544
Income taxes (14,993) (10,407) 6,093 (19,307)
Net income/(loss) $46,771 $32,071 $(14,605) $64,237
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(6,067) $(6,067)
Legal settlements (2,850) - - (2,850)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Long-term incentive compensation - - 216 216
Other - - (2,665) (2,665)
Total $(2,850) $(2,352) $(8,516) $(13,718)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(5,259) $(5,259)
Legal settlements (2,152) - - (2,152)
Amortization of reacquired franchise agreements - (1,806) - (1,806)
Long-term incentive compensation - - 213 213
Other - - (2,665) (2,665)
Total $(2,152) $(1,806) $(7,711) $(11,669)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

(in thousands)(unaudited)

2026 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $1,320,762 $700,942 $- $2,021,704
Cost of services provided and goods sold 1,005,150 346,357 - 1,351,507
Selling, general and administrative expenses 75,314 206,335 59,344 340,993
Depreciation 17,484 25,477 36 42,997
Amortization 78 8,185 - 8,263
Other operating expense 7,432 78 230 7,740
Total costs and expenses 1,105,458 586,432 59,610 1,751,500
Income/(loss) from operations 215,304 114,510 (59,610) 270,204
Interest expense (158) (466) (3,774) (4,398)
Intercompany interest income/(expense) 19,484 13,661 (33,145) -
Other income—net 285 31 10,755 11,071
Income/(expense) before income taxes 234,915 127,736 (85,774) 276,877
Income taxes (56,088) (29,899) 14,763 (71,224)
Net income/(loss) $178,827 $97,837 $(71,011) $205,653
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(24,285) $(24,285)
Legal settlements (7,253) - (308) (7,561)
Amortization of reacquired franchise agreements - (7,056) - (7,056)
Long-term incentive compensation - - (6,904) (6,904)
Acquisition expense (8) (1,953) - (1,961)
Total $(7,261) $(9,009) $(31,497) $(47,767)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(20,638) $(20,638)
Long-term incentive compensation - - (6,189) (6,189)
Legal settlements (5,491) - (238) (5,729)
Amortization of reacquired franchise agreements - (5,412) - (5,412)
Acquisition expense (6) (1,497) - (1,503)
Excess tax expense on stock compensation - - (1,022) (1,022)
Total $(5,497) $(6,909) $(28,087) $(40,493)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025

(in thousands)(unaudited)

2025 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $1,211,341 $679,300 $- $1,890,641
Cost of services provided and goods sold 951,466 338,312 - 1,289,778
Selling, general and administrative expenses 76,861 183,856 50,968 311,685
Depreciation 15,863 24,899 36 40,798
Amortization 78 7,635 - 7,713
Other operating expense/(income) 3,155 (80) - 3,075
Total costs and expenses 1,047,423 554,622 51,004 1,653,049
Income/(loss) from operations 163,918 124,678 (51,004) 237,592
Interest expense (150) (394) (685) (1,229)
Intercompany interest income/(expense) 16,436 11,930 (28,366) -
Other income - net 170 58 13,742 13,970
Income/(expense) before income taxes 180,374 136,272 (66,313) 250,333
Income taxes (45,353) (32,344) 15,851 (61,846)
Net income/(loss) $135,021 $103,928 $(50,462) $188,487
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(24,374) $(24,374)
Amortization of reacquired franchise agreements - (7,056) - (7,056)
Long-term incentive compensation - - (3,294) (3,294)
Legal settlements (2,850) - - (2,850)
Other - - (2,665) (2,665)
Total $(2,850) $(7,056) $(30,333) $(40,239)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(20,576) $(20,576)
Amortization of reacquired franchise agreements - (5,419) - (5,419)
Long-term incentive compensation - - (2,915) (2,915)
Legal settlements (2,152) - - (2,152)
Excess tax benefits on stock compensation - - 513 513
Other - - (2,665) (2,665)
Total $(2,152) $(5,419) $(25,643) $(33,214)

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the three months ended September 30, 2026 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $65,708 $30,140 $(24,200) $71,648
Add/(deduct):
Interest expense 54 145 1,898 2,097
Income taxes 20,270 9,152 (4,362) 25,060
Depreciation 5,791 8,624 12 14,427
Amortization 25 2,949 - 2,974
EBITDA 91,848 51,010 (26,652) 116,206
Add/(deduct):
Intercompany interest expense/(income) (6,766) (4,574) 11,340 -
Interest income (113) (5) (177) (295)
Legal settlements 6,705 - 308 7,013
Stock option expense - - 5,984 5,984
Long-term incentive compensation - - 3,151 3,151
Acquisition expense - 1,726 - 1,726
Adjusted EBITDA $91,674 $48,157 $(6,046) $133,785
Chemed
For the three months ended September 30, 2025 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $46,771 $32,071 $(14,605) $64,237
Add/(deduct):
Interest expense 56 132 269 457
Income taxes 14,993 10,407 (6,093) 19,307
Depreciation 5,354 8,298 12 13,664
Amortization 26 2,544 - 2,570
EBITDA 67,200 53,452 (20,417) 100,235
Add/(deduct):
Intercompany interest expense/(income) (5,685) (4,030) 9,715 -
Interest income (69) (25) (2,462) (2,556)
Stock option expense - - 6,067 6,067
Legal settlements 2,850 - - 2,850
Long-term incentive compensation - - (216) (216)
Other - - 2,665 2,665
Adjusted EBITDA $64,296 $49,397 $(4,648) $109,045

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the nine months ended September 30, 2026 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $178,827 $97,837 $(71,011) $205,653
Add/(deduct):
Interest expense 158 466 3,774 4,398
Income taxes 56,088 29,899 (14,763) 71,224
Depreciation 17,484 25,477 36 42,997
Amortization 78 8,185 - 8,263
EBITDA 252,635 161,864 (81,964) 332,535
Add/(deduct):
Intercompany interest expense/(income) (19,484) (13,661) 33,145 -
Interest income (274) (31) (1,094) (1,399)
Stock option expense - - 24,285 24,285
Legal settlements 7,253 - 308 7,561
Long-term incentive compensation - - 6,904 6,904
Acquisition expense 8 1,953 - 1,961
Adjusted EBITDA $240,138 $150,125 $(18,416) $371,847
Chemed
For the nine months ended September 30, 2025 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $135,021 $103,928 $(50,462) $188,487
Add/(deduct):
Interest expense 150 394 685 1,229
Income taxes 45,353 32,344 (15,851) 61,846
Depreciation 15,863 24,899 36 40,798
Amortization 78 7,635 - 7,713
EBITDA 196,465 169,200 (65,592) 300,073
Add/(deduct):
Intercompany interest expense/(income) (16,436) (11,930) 28,366 -
Interest income (176) (58) (6,952) (7,186)
Stock option expense - - 24,374 24,374
Long-term incentive compensation - - 3,294 3,294
Legal settlements 2,850 - - 2,850
Other - - 2,665 2,665
Adjusted EBITDA $182,703 $157,212 $(13,845) $326,070

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended September 30, 2026 2025 Nine Months Ended September 30, 2026 2025
Net income as reported $71,648 $64,237 $205,653 $188,487
Add/(deduct) pre-tax cost of:
Stock option expense 5,984 6,067 24,285 24,374
Legal settlements 7,013 2,850 7,561 2,850
Amortization of reacquired franchise agreements 2,352 2,352 7,056 7,056
Long-term incentive compensation 3,151 (216) 6,904 3,294
Acquisition expense 1,726 - 1,961 -
Other - 2,665 - 2,665
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (3,670) (2,049) (8,296) (6,512)
Excess tax expense/(benefit) on stock compensation 521 - 1,022 (513)
Adjusted net income $88,725 $75,906 $246,146 $221,701
Diluted Earnings Per Share As Reported
Net income $5.45 $4.46 $15.43 $12.89
Average number of shares outstanding 13,135 14,409 13,329 14,620
Adjusted Diluted Earnings Per Share
Adjusted net income $6.75 $5.27 $18.47 $15.16
Adjusted average number of shares outstanding 13,135 14,409 13,329 14,620
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

OPERATING STATISTICS Net revenue ($000) Three Months Ended September 30, 2026 2025 Nine Months Ended September 30, 2026 2025
Homecare $405,969 $362,405 $1,168,407 $1,072,014
Inpatient 36,407 33,099 108,006 100,145
Continuous care 21,159 19,946 58,689 68,222
Other 6,421 5,807 18,204 16,898
Subtotal $469,956 $421,257 $1,353,306 $1,257,279
Room and board, net (3,982) (3,859) (11,178) (11,277)
Contractual allowances (7,743) (3,571) (17,663) (9,875)
Medicare cap allowance (828) (6,086) (3,703) (24,786)
Total $457,403 $407,741 $1,320,762 $1,211,341
Net revenue as a percent of total before Medicare cap allowances
Homecare 86.4% 86.0% 86.3% 85.3%
Inpatient 7.7 7.9 8.0 8.0
Continuous care 4.5 4.7 4.3 5.4
Other 1.4 1.4 1.4 1.3
Subtotal 100.0 100.0 100.0 100.0
Room and board, net (0.8) (0.8) (0.8) (0.9)
Contractual allowances (1.7) (0.8) (1.3) (0.8)
Medicare cap allowance (0.2) (1.4) (0.3) (2.0)
Total 97.3% 97.0% 97.6% 96.3%
Days of care
Homecare 1,872,071 1,685,859 5,356,050 4,980,883
Nursing home 312,663 309,192 910,534 923,458
Respite 12,502 12,184 35,684 33,619
Subtotal routine homecare and respite 2,197,236 2,007,235 6,302,268 5,937,960
Inpatient 30,494 28,530 90,671 86,447
Continuous care 19,683 18,309 55,065 62,576
Total 2,247,413 2,054,074 6,448,004 6,086,983
Number of days in relevant time period 92 92 273 273
Average daily census (days)
Homecare 20,348 18,325 19,619 18,245
Nursing home 3,399 3,361 3,335 3,383
Respite 136 132 131 123
Subtotal routine homecare and respite 23,883 21,818 23,085 21,751
Inpatient 331 310 332 317
Continuous care 214 199 202 229
Total 24,428 22,327 23,619 22,297
Total Admissions 18,995 17,714 57,514 53,398
Total Discharges 18,426 17,348 55,130 52,931
Average length of stay (days) 103.5 109.7 102.5 121.9
Median length of stay (days) 17.0 18.0 16.0 18.0
ADC by major diagnosis
Cerebro 44.1% 44.1% 44.4% 44.6%
Neurological 11.2 11.6 11.1 11.8
Cancer 9.2 10.1 9.4 9.8
Cardio 16.8 15.9 16.6 16.0
Respiratory 8.1 7.7 7.9 7.4
Other 10.6 10.6 10.6 10.4
Total 100.0% 100.0% 100.0% 100.0%
Admissions by major diagnosis
Cerebro 28.0% 27.1% 27.5% 27.6%
Neurological 6.7 6.9 6.9 6.8
Cancer 24.7 26.6 24.3 25.9
Cardio 14.9 14.3 15.3 14.7
Respiratory 12.3 10.5 12.2 10.9
Other 13.4 14.6 13.8 14.1
Total 100.0% 100.0% 100.0% 100.0%
Estimated uncollectible accounts as a percent of revenues 1.2% 0.9% 1.3% 0.8%
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 39.0 37.5 n.a. n.a.
Days of revenue outstanding- including unapplied Medicare payments 37.4 34.0 n.a. n.a.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Market risk

As filed, 591 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At September 30, 2026, the Company has $236.0 million of variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Controls and procedures

As filed, 865 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision of the Company’s President and Chief Executive Officer and with the participation of the Executive Vice President, Chief Financial Officer and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer and Executive Vice President, Chief Financial Officer and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 169 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-07-01 to 2026-09-30$690.9mus-gaap:Revenues
Revenue9 months2026-01-01 to 2026-09-30$2.02bnus-gaap:Revenues
Cost of revenue3 months2026-07-01 to 2026-09-30$458.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2026-01-01 to 2026-09-30$1.35bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2026-07-01 to 2026-09-30$111.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2026-01-01 to 2026-09-30$341.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2026-07-01 to 2026-09-30$96.4mus-gaap:OperatingIncomeLoss
Operating income9 months2026-01-01 to 2026-09-30$270.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2026-07-01 to 2026-09-30$2.1mus-gaap:InterestExpense
Interest expense9 months2026-01-01 to 2026-09-30$4.4mus-gaap:InterestExpense
Income tax3 months2026-07-01 to 2026-09-30$25.1mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2026-01-01 to 2026-09-30$71.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-07-01 to 2026-09-30$71.6mus-gaap:NetIncomeLoss
Net income9 months2026-01-01 to 2026-09-30$205.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-07-01 to 2026-09-30$5.45us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2026-01-01 to 2026-09-30$15.43us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-07-01 to 2026-09-30$5.49us-gaap:EarningsPerShareBasic
Basic EPS9 months2026-01-01 to 2026-09-30$15.46us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-07-01 to 2026-09-3013,135,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2026-01-01 to 2026-09-3013,329,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2026-01-01 to 2026-09-30$229.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2026-01-01 to 2026-09-30$51.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2026-01-01 to 2026-09-30$25.2mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2026-01-01 to 2026-09-30$350.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-09-30$48.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-09-30$365.7mus-gaap:AssetsCurrent
Total assetsAt period end2026-09-30$1.72bnus-gaap:Assets
Current liabilitiesAt period end2026-09-30$330.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-09-30$857.0mus-gaap:Liabilities
Long-term debtAt period end2026-09-30$236.0mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2026-09-30$861.4mus-gaap:StockholdersEquity
Shares outstandingAt period end2026-09-3013,014,915 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0000019584-26-000024. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.